In the study conducted by Çelik and Aktaş, a marked reduction in NLR and SII was noted after six months of IL-17 and IL-23 inhibitor treatment in psoriasis patients, although no significant changes were observed in PLR or RDW [22]. Here, IL17A is linked to psoriasis.